![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Eyetech Pharmaceuticals Pfizer |
---|---|
Information provided by: | Eyetech Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00088192 |
To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor’s other clinical studies with this drug for AMD, until such time as the patient’s lesion is considered to have resolved or stabilized in the opinion of the treating ophthalmologist, or product becomes commercially available.
Condition | Intervention |
---|---|
Macular Degeneration |
Drug: pegaptanib sodium |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Open Label, Non-Comparative Protocol for Use of Intravitreous Pegaptanib Sodium Injection Every 6 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD) |
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
General Criteria:
Exclusion Criteria:
Study ID Numbers: | EOP1010 |
Study First Received: | July 21, 2004 |
Last Updated: | August 29, 2005 |
ClinicalTrials.gov Identifier: | NCT00088192 |
Health Authority: | United States: Food and Drug Administration |
AMD Age-Related Macular Degeneration Exudative Subfoveal Age Related Macular Degeneration with Subfoveal Choroidal Neovascularization |
Eye Diseases Retinal Degeneration Macular Degeneration Neovascularization, Pathologic |
Retinal Diseases Retinal degeneration Choroidal Neovascularization |